Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000899243-21-024300
Filing Date
2021-06-16
Accepted
2021-06-16 20:07:26
Documents
1
Period of Report
2021-06-16

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 5928
  Complete submission text file 0000899243-21-024300.txt   7488
Mailing Address 719 SECOND AVENUE SUITE 1402 SEATTLE WA 98104
Business Address 719 SECOND AVENUE SUITE 1402 SEATTLE WA 98104 703-966-0695
Biomatics Capital Partners, L.P. (Reporting) CIK: 0001672431 (see all company filings)

State of Incorp.: DE | Fiscal Year End: 1231
Type: 3 | Act: 34 | File No.: 001-40489 | Film No.: 211023005

Mailing Address 500 TECHNOLOGY SQUARE CAMBRIDGE MA 02139
Business Address 500 TECHNOLOGY SQUARE CAMBRIDGE MA 02139 (978) 501-3026
Verve Therapeutics, Inc. (Issuer) CIK: 0001840574 (see all company filings)

EIN.: 824800132 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations